40.38 0.00 (0.00%)
After hours: 4:59PM EDT
|Bid||40.25 x 500|
|Ask||41.10 x 600|
|Day's Range||39.39 - 41.12|
|52 Week Range||11.30 - 45.85|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Arena Pharmaceuticals Inc’s (NASDAQ:ARNA) announced its latest earnings update in December 2017, which indicated that losses became smaller relative to the prrior year’s level – great news for investors Below,Read More...
The biotech sector was in focus last week with Alexion gaining on positive data on PNH candidate, Arena surges on ulcerative drug data, Solid Biosciences' stock suffering a crash and Prothena teaming up with Celgene.
Arena Pharmaceuticals Inc. ticked lower Tuesday after the biotech company announced a secondary offering of shares. Arena shares declined 1.9% after hours, following a surge of 29% to close the regular ...
Arena gapped up by nearly a third Tuesday after its ulcerative colitis drug proved strong in a Phase 2 trial.
Shares of Arena Pharmaceuticals Inc. shot up 34% in premarket trade Tuesday, after the drugmaker reported positive results from a phase 2 trial of its treatment for ulcerative colitis. The rally comes ...
Arena rocketed nearly 30% late Monday after its inflammatory bowel disease drug hit each of its goals in a midstage trial.
Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study. The company is banking on etrasimod, along with its pulmonary arterial hypertension drug, after shifting its focus away from its weight-loss treatment due to underwhelming sales. Arena sold the global commercialization rights to the weight-loss drug, Belviq, to Japanese drugmaker Eisai Co Ltd early last year.
Arena (ARNA) reports narrower-than-expected Q4 loss. However, revenues decrease year over year. The company is likely to advance ralinepag in phase III study in the second half of 2018.